About

Siyu Shi is an Associate at F-Prime Capital and works across the healthcare sub-sectors including Therapeutics, MedTech, and Healthcare IT and Services, and also closely with the Eight Roads Ventures China team to manage F-Prime’s existing and new investment efforts in China. Prior to joining F-Prime Capital, Siyu consulted for biotech start-ups and investment funds.

Siyu’s research focused on artificial intelligence and data science in healthcare at the Stanford Machine Learning Group, including projects in rare disease detection in imaging, self-supervised learning with sound data, transformer model for heart attack prediction, causal inference for heterogenous treatment effects, and oncology outcome research. Previously, she also worked on biomaterials and peptide chemistry at Rice University and MIT.

Siyu holds an MD and a MS in Epidemiology from Stanford School of Medicine, as well as an MBA from Stanford Graduate School of Business.

  • FCB Health is a health insurance and services company that aims to resolve the longstanding financial burden of rising medical expenses in rural China.

     

  • K36 Therapeutics was established with the mission to translate epigenetic modulation of oncogenic pathways into first-in-class small molecule therapies. Its vision is to create breakthrough therapies for the unmet medical needs of cancer patients worldwide.

  • MediTrust Health is a provider of payment services for medical healthcare. The company is dedicated to helping patients solve their own medical payment problems through financial insurance, manage medical expenses more efficiently, and providing value to patients around medical finance, curative effect insurance, and drug benefits, helping patients manage their medical expenses. Learn more at www.meditrusthealth.com.

  • OriGynMED is a developer of medical devices designed for women’s health. The company is mainly engaged in developing various gynecology medical devices such as hysterectomy cold knife and functional hysteroscope, enabling client to improve treatment effect. Learn more at www.origynmed.com.

  • Silexon is an emerging AI-empowered technology company which aims to create an open AI platform for strategic collaboration in order to facilitate data-driven life science research and empower drug R&D process, and ultimately provide patients with greater access to innovative drugs for unmet medical needs.  Learn more at www.silexon.tech.

  • Skyline Therapeutics (formerly Geneception) is a fully-integrated gene and cell therapy based in Hangzhou and Shanghai, China.  Founded by F-Prime Capital, Eight Roads Ventures China and Lilly Asia Ventures in 2018, Skyline’s mission is to become a preeminent gene and cell therapy company, working to deliver world-class therapeutics for patients in China and globally.